Regarding hematologic toxicity, most patients in the two treatment groups experienced only mild adverse effects, without any deaths. The incidence of grade 3 - 4 agranulocytosis in the high-dose cisplatin group was statistically significantly higher than that of low-dose cisplatin group (11.76% and 0% respectively, p<0.05).